TY - JOUR
T1 - Immunotherapy in Sarcoma
T2 - Future Horizons
AU - Burgess, Melissa
AU - Gorantla, Vikram
AU - Weiss, Kurt
AU - Tawbi, Hussein
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/11/3
Y1 - 2015/11/3
N2 - Immunologic approaches to cancer are over a century old. Over the years, the strategy has been fine-tuned from inciting infections in subjects to inhibiting negative regulatory signals from the innate immune system. Sarcomas are among the first tumors to be considered for immune interventions. From Coley’s toxin to cytokine-based therapies to adoptive cell therapy, there have been numerous immunotherapeutic investigations in this patient population. A promising strategy includes adoptive T cell therapy which has been studied in small cohorts of synovial sarcoma, a subtype that is known to widely express the cancer testis antigen, NY-ESO-1. Additionally, recent data in metastatic melanoma and renal cell carcinoma demonstrate the utility and tremendous efficacy of immune checkpoint blockade with increased rates of durable responses compared to standard therapies. Responses in traditionally “non-immunogenic” tumors, such as lung and bladder cancers, provide ample rationale for the study of immune checkpoint inhibitors in sarcoma. While immunotherapy has induced some responses in sarcomas, further research will help clarify optimal patient selection for future clinical trials and new combinatorial immunotherapeutic strategies.
AB - Immunologic approaches to cancer are over a century old. Over the years, the strategy has been fine-tuned from inciting infections in subjects to inhibiting negative regulatory signals from the innate immune system. Sarcomas are among the first tumors to be considered for immune interventions. From Coley’s toxin to cytokine-based therapies to adoptive cell therapy, there have been numerous immunotherapeutic investigations in this patient population. A promising strategy includes adoptive T cell therapy which has been studied in small cohorts of synovial sarcoma, a subtype that is known to widely express the cancer testis antigen, NY-ESO-1. Additionally, recent data in metastatic melanoma and renal cell carcinoma demonstrate the utility and tremendous efficacy of immune checkpoint blockade with increased rates of durable responses compared to standard therapies. Responses in traditionally “non-immunogenic” tumors, such as lung and bladder cancers, provide ample rationale for the study of immune checkpoint inhibitors in sarcoma. While immunotherapy has induced some responses in sarcomas, further research will help clarify optimal patient selection for future clinical trials and new combinatorial immunotherapeutic strategies.
KW - Immune checkpoint blockade
KW - Immunosurveillance
KW - Immunotherapy
KW - Programmed death-1 (PD-1)
KW - Soft tissue sarcoma
KW - Tumor-infiltrating lymphocyte (TIL)
UR - http://www.scopus.com/inward/record.url?scp=84942875549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942875549&partnerID=8YFLogxK
U2 - 10.1007/s11912-015-0476-7
DO - 10.1007/s11912-015-0476-7
M3 - Review article
C2 - 26423769
AN - SCOPUS:84942875549
SN - 1523-3790
VL - 17
JO - Current oncology reports
JF - Current oncology reports
IS - 11
M1 - 52
ER -